60 Degrees Pharmaceuticals

SXTP · NASDAQ

$0.9222+$0.0229 (+2.55%)TodayMarket closed ·
Prev close $0.8993

Latest news

  • News

    60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

  • NewsMohd Haider

    60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

  • News

    60 Degrees Pharmaceuticals Enters Exclusive Option Agreement With Florida State's Research Foundation Regarding IP To Develop Castanospermine For Multiple Tick-Borne Diseases

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Announces 2025 Annual Results

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

  • NewsAvi Kapoor

    Dow Gains Over 100 Points; Steel Dynamics Posts Downbeat Earnings

  • NewsAvi Kapoor

    Why Baker Hughes Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

  • NewsAvi Kapoor

    Dow Jumps 300 Points; Procter & Gamble Shares Gain After Q2 Results

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • News

    Market-Moving News for July 15th

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • NewsAvi Kapoor

    Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings

  • NewsAvi Kapoor

    Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals Announces 2024 Annual Results

  • NewsAvi Kapoor

    US Stocks Mixed; General Dynamics Earnings Top Views

  • NewsRishabh Mishra

    US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

  • NewsAvi Kapoor

    Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

  • NewsAvi Kapoor

    Crude Oil Down 3%; Netflix Earnings Top Estimates

  • NewsVaishali Prayag

    Why Are 60 Degrees Pharmaceuticals Shares Up By 50% Today?

  • NewsAvi Kapoor

    Why Selective Insurance Group Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session

  • NewsAvi Kapoor

    Gold Down 2%; SLB Posts Upbeat Earnings

  • NewsAvi Kapoor

    Dow Tumbles Over 100 Points; American Express Earnings Beat Views

  • NewsAvi Kapoor

    Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.